Literature DB >> 11551849

Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery.

J Nygren1, C Carlsson-Skwirut, K Brismar, A Thorell, O Ljungqvist, P Bang.   

Abstract

We have studied the effects of insulin on the bioavailability of insulin-like growth factor (IGF) I in insulin-resistant patients after surgery. Serum levels of total IGF-I (tIGF-I), free IGF (fIGF)-I, fIGF-II, and IGF-binding protein (IGFBP) 1 and IGFBP-3 proteolytic activity (IGFBP-3-PA), determined on the day before surgery and on the 1st postoperative day, were related to insulin sensitivity measured by a hyperinsulinemic, normoglycemic clamp. Before surgery, the decreased tIGF-I (P < 0.05) in response to insulin infusion was accompanied by an 18% reduction of IGFBP-1 (P < 0.001), while IGFBP-3-PA remained unchanged. Levels of fIGF-I and fIGF-II were not changed by insulin infusions. After surgery, IGFBP-3-PA increased (P < 0.05) during insulin infusion, and this was associated with an increase in tIGF-I (P < 0.001) and fIGF-I (P < 0.01), while no significant change was found in fIGF-II. The reduction in IGFBP-1 in response to insulin infusion was not affected by surgery. The change in IGFBP-3-PA during insulin infusion after surgery was related to the corresponding change in fIGF-I (r(2) = 0.26, P < 0.05) and postoperative insulin sensitivity (r(2) = -0.22, P < 0.05). These data suggest that increased IGFBP-3-PA during insulin infusion after surgery governs the increased levels of fIGF-I, while insulin-induced suppression of IGFBP-1 was not affected by surgery. We propose that, in catabolic, postoperative patients, increased levels of insulin from exogenous or, possibly, endogenous sources (nutritionally induced) may be a signal to increase IGF-I bioavailability by increased expression of IGFBP-3-PA to counteract further deterioration in glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551849     DOI: 10.1152/ajpendo.2001.281.4.E736

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  5 in total

Review 1.  Potential beneficial mechanisms of insulin (glucose-potassium) in acute myocardial infarction.

Authors:  I C C van der Horst; F Zijlstra
Journal:  Neth Heart J       Date:  2005-06       Impact factor: 2.380

Review 2.  Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.

Authors:  P Spallarossa; A Barsotti; R Cordera; G Ghigliotti; D Maggi; C Brunelli
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

Review 3.  Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity.

Authors:  J A M J L Janssen; A J van der Lely; S W J Lamberts
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

Review 4.  Insulin: a wonder drug in the critically ill?

Authors:  A B Johan Groeneveld; Albertus Beishuizen; Frans C Visser
Journal:  Crit Care       Date:  2002-02-08       Impact factor: 9.097

5.  Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men.

Authors:  Satoshi Teramukai; Thomas Rohan; Kyong-Yeon Lee; Hiroyuki Eguchi; Takashi Oda; Suminori Kono
Journal:  Jpn J Cancer Res       Date:  2002-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.